Growth Metrics

Vertex Pharmaceuticals (VRTX) Consolidated Net Income (2009 - 2026)

Vertex Pharmaceuticals' quarterly Consolidated Net Income came in at $1.0 billion in Q1 2026, up 59.59% year-on-year from $646.3 million in Q1 2025, and down 13.41% quarter-over-quarter from $1.2 billion in Q4 2025.

Vertex Pharmaceuticals has reported Consolidated Net Income for 17 years, with the latest figure at $1.0 billion in Q1 2026.

  • For the quarter ending Q1 2026, Consolidated Net Income rose 59.59% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.3 billion (up 538.7% YoY), and the FY2025 full-year result was $4.0 billion, up 838.09% from the prior year.
  • Consolidated Net Income for Q1 2026 stood at $1.0 billion, down from $1.2 billion in the prior quarter.
  • The five-year high for Consolidated Net Income was $1.2 billion in Q4 2025, with the low at -$3.6 billion in Q2 2024.
  • Average Consolidated Net Income over 5 years is $670.0 million, with a median of $930.5 million recorded in 2022.
  • Year-over-year, Consolidated Net Income soared 1109.7% in 2022 and tumbled 492.44% in 2024.
  • Tracing VRTX's Consolidated Net Income over 5 years: stood at $818.9 million in 2022, then rose by 18.31% to $968.8 million in 2023, then slipped by 5.76% to $913.0 million in 2024, then surged by 30.46% to $1.2 billion in 2025, then slipped by 13.41% to $1.0 billion in 2026.
  • The last three Consolidated Net Income figures came in at $1.0 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.99 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -8.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.03 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.40 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 727.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 205.99 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - -453.82 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.03 Bn
Dec 31, 2025 1.19 Bn
Sep 30, 2025 1.08 Bn
Jun 30, 2025 1.03 Bn
Mar 31, 2025 646.30 Mn
Dec 31, 2024 913.00 Mn
Sep 30, 2024 1.05 Bn
Jun 30, 2024 -3.59 Bn
Mar 31, 2024 1.10 Bn
Dec 31, 2023 968.80 Mn
Sep 30, 2023 1.04 Bn
Jun 30, 2023 915.70 Mn
Mar 31, 2023 699.80 Mn
Dec 31, 2022 818.90 Mn
Sep 30, 2022 930.50 Mn
Jun 30, 2022 810.50 Mn
Mar 31, 2022 762.10 Mn
Dec 31, 2021 770.10 Mn
Sep 30, 2021 851.90 Mn
Jun 30, 2021 67.00 Mn
Mar 31, 2021 653.10 Mn
Dec 31, 2020 604.19 Mn
Sep 30, 2020 667.43 Mn
Jun 30, 2020 837.27 Mn
Mar 31, 2020 602.75 Mn
Dec 31, 2019 583.23 Mn
Sep 30, 2019 57.52 Mn
Jun 30, 2019 267.43 Mn
Mar 31, 2019 268.63 Mn
Dec 31, 2018 1.53 Bn
Sep 30, 2018 128.46 Mn
Jun 30, 2018 206.25 Mn
Mar 31, 2018 227.30 Mn
Dec 31, 2017 102.19 Mn
Sep 30, 2017 -290.97 Mn
Jun 30, 2017 31.17 Mn
Mar 31, 2017 249.55 Mn
Dec 31, 2016 27.76 Mn
Sep 30, 2016 -39.54 Mn
Jun 30, 2016 -36.15 Mn
Mar 31, 2016 -36.10 Mn
Dec 31, 2014 -209,000.00
Sep 30, 2014 -64,000.00
Jun 30, 2014 -293,000.00
Mar 31, 2014 -346,000.00
Dec 31, 2013 -163.63 Mn
Sep 30, 2013 -7.21 Mn
Jun 30, 2013 -2.81 Mn
Mar 31, 2013 -5.73 Mn
Dec 31, 2012 -78.08 Mn
Sep 30, 2012 -26.47 Mn
Jun 30, 2012 -34.47 Mn
Mar 31, 2012 87.88 Mn
Dec 31, 2011 188.14 Mn
Sep 30, 2011 228.45 Mn
Mar 31, 2011 -176.10 Mn
Dec 31, 2010 -180.39 Mn
Sep 30, 2010 -208.96 Mn
Jun 30, 2010 -200.01 Mn
Mar 31, 2010 -163.78 Mn
Dec 31, 2009 -150.95 Mn
Sep 30, 2009 -149.57 Mn
Jun 30, 2009 -159.00 Mn
Mar 31, 2009 -162.67 Mn